# Beijing Greatsun Biomedical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-greatsun-biomedical-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.greatsunbio.cn
- Latest round: Series A (May 12, 2022)
- Investors on record: 3

## About

Based in Beijing, China, and established in 2011. Beijing Greatsun Biomedical Technology Co., Ltd. is a biomedical company that focuses on the R&D, and commercialization of innovative drugs for cancers and major diseases. The company's founder is Dr. Guanghua Cui, and its CTO is Dr. Ziyi Yang. 

The company has built three technology platforms. The receptor active targeting agent technology platform on which a series of active targeting new agents can be developed. Macromolecular therapeutic drugs can be developed, based on the yeast expression system platform. And based on the protein drug long-acting technology platform, it can design a series of long-acting protein drugs. Those new drugs can be used in the fields of tumor, endocrine, blood, and nervous system diseases.

The company will use the Series A funding to promote the R&D of new drugs, introduce talents, and product commercialization.

## Funding rounds

- Series A, May 12, 2022 — Sihuan Pharmaceutical, Digital China Capital, Jinggang Capital

## Investors

- Sihuan Pharmaceutical — Series A
- Digital China Capital (https://capitalatlas.ai/funds/digital-china-capital) — Series A
- Jinggang Capital (https://capitalatlas.ai/funds/jinggang-capital) — Series A